What is Corvidia?
Corvidia Therapeutics is dedicated to pioneering transformative therapies for cardio-renal diseases. The company's research and development efforts are concentrated on potential treatments for chronic kidney disease associated with atherosclerotic cardiovascular disease and inflammation, as well as high triglyceride-induced acute pancreatitis. Established in 2015 and headquartered in Waltham, Massachusetts, Corvidia is strategically positioned to address critical unmet needs in cardiovascular and renal health.
How much funding has Corvidia raised?
Corvidia has raised a total of $86M across 2 funding rounds:
Series A
$26M
Series B
$60M
Series A (2016): $26M with participation from Apple Tree Partners and Sofinnova Partners
Series B (2018): $60M, investors not publicly disclosed
Key Investors in Corvidia
Apple Tree Partners
Apple Tree Partners is an incubator and accelerator focused on foundational science for its portfolio companies, offering comprehensive services from compound screening to preclinical pharmacology.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, acting as a hands-on company builder across the entire value chain of investments.
What's next for Corvidia?
With the recent infusion of capital, Corvidia is poised for significant advancement in its clinical programs. The major strategic investment suggests a focus on scaling operations, advancing late-stage clinical trials, and potentially preparing for regulatory submissions. This funding will be instrumental in driving Corvidia's mission to bring novel cardio-renal therapies to patients, reinforcing its position as a key player in the biopharmaceutical sector. The company's trajectory indicates a move towards commercialization and broader market impact.
See full Corvidia company page
